drugset / Trial / NCT06078306
CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).
NaSingle-groupOpen-labelTreatment
Summary
Clinical trial for the safety and efficacy of induction chemotherapy with VA regime and bridging CD19CD22 CAR-T therapy in adult patients with newly diagnosed high-risk and Ph- B-ALL
Timeline
- Start
- 2024-04-20
- Primary completion
- 2024-09-10
- Completion
- 2025-09-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |
| Subject | CD19CD22 CAR-T | Cell therapy | — | Intravenous |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |